Osteoporosis International

, Volume 23, Issue 1, pp 351–363 | Cite as

Sustained efficacy and safety of bazedoxifene in preventing fractures in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled study

  • S. L. Silverman
  • A. A. Chines
  • D. L. Kendler
  • A. W. C. Kung
  • C. S. Teglbjærg
  • D. Felsenberg
  • N. Mairon
  • G. D. Constantine
  • J. D. Adachi
  • for the Bazedoxifene Study Group
Original Article

Abstract

Summary

In this 2-year extension of a 3-year study, bazedoxifene showed sustained efficacy in preventing new vertebral fractures in postmenopausal women with osteoporosis and in preventing non-vertebral fractures in higher-risk women. Bazedoxifene significantly increased bone mineral density and reduced bone turnover versus placebo and was generally safe and well tolerated.

Introduction

This study evaluated the efficacy and safety of bazedoxifene for the treatment of postmenopausal osteoporosis over 5 years.

Methods

A total of 4,216 postmenopausal women with osteoporosis were enrolled in this 2-year extension of a 3-year, randomized, double-blind, placebo-controlled, phase 3 trial. In the core study (N = 7,492), subjects received bazedoxifene 20 or 40 mg/day, raloxifene 60 mg/day, or placebo. The raloxifene arm was discontinued after 3 years; subjects receiving bazedoxifene 40 mg were transitioned to bazedoxifene 20 mg after 4 years. Five-year findings are reported for bazedoxifene 20 and 40/20 mg and placebo. Endpoints included incidence of new vertebral fractures (primary) and non-vertebral fractures, and changes in bone mineral density (BMD) and bone turnover markers.

Results

At 5 years, the incidence of new vertebral fractures in the intent-to-treat population was significantly lower with bazedoxifene 20 mg (4.5%) and 40/20 mg (3.9%) versus placebo (6.8%; P < 0.05), with relative risk reductions of 35% and 40%, respectively. Non-vertebral fracture incidence was similar among groups. In a subgroup of higher-risk women (n = 1,324; femoral neck T-score ≤−3.0 and/or ≥1 moderate or severe or ≥2 mild vertebral fracture[s]), bazedoxifene 20 mg reduced non-vertebral fracture risk versus placebo (37%; P = 0.06); combined data for bazedoxifene 20 and 40/20 mg reached statistical significance (34% reduction; P < 0.05). Bazedoxifene significantly increased BMD and reduced bone turnover versus placebo (P < 0.05) and was generally safe and well tolerated.

Conclusions

The findings support a sustained anti-fracture effect of bazedoxifene on new vertebral fractures in postmenopausal osteoporotic women and on non-vertebral fractures in the higher-risk subgroup of women.

Keywords

Bazedoxifene Fracture Osteoporosis Postmenopausal SERMs 

References

  1. 1.
    Atik OS, Gunal I, Korkusuz F (2006) Burden of osteoporosis. Clin Orthop Relat Res 443:19–24PubMedCrossRefGoogle Scholar
  2. 2.
    Ioannidis G, Papaioannou A, Hopman WM, Khtar-Danesh N, Anastassiades T, Pickard L, Kennedy CC, Prior JC, Olszynski WP, Davison KS, Goltzman D, Thabane L, Gafni A, Papadimitropoulos EA, Brown JP, Josse RG, Hanley DA, Adachi JD (2009) Relation between fractures and mortality: results from the Canadian Multicentre Osteoporosis Study. CMAJ 181:265–271PubMedCrossRefGoogle Scholar
  3. 3.
    National Osteoporosis Foundation (2010) Fast facts on osteoporosis. http://www.nof.org/osteoporosis/diseasefacts.htm. Accessed 4 August 2010
  4. 4.
    North American Menopause Society (2010) Management of osteoporosis in postmenopausal women: 2010 position statement of The North American Menopause Society. Menopause 17:25–54CrossRefGoogle Scholar
  5. 5.
    Salaffi F, Cimmino MA, Malavolta N, Carotti M, Di ML, Scendoni P, Grassi W (2007) The burden of prevalent fractures on health-related quality of life in postmenopausal women with osteoporosis: the IMOF study. J Rheumatol 34:1551–1560PubMedGoogle Scholar
  6. 6.
    Silverman SL, Shen W, Minshall ME, Xie S, Moses KH (2007) Prevalence of depressive symptoms in postmenopausal women with low bone mineral density and/or prevalent vertebral fracture: results from the Multiple Outcomes of Raloxifene Evaluation (MORE) study. J Rheumatol 34:140–144PubMedGoogle Scholar
  7. 7.
    Ostermiller J, Hatz J (2008) Osteoporosis breaks bones and budgets. NCSL Legisbrief 16:1–2PubMedGoogle Scholar
  8. 8.
    Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A (2007) Incidence and economic burden of osteoporosis-related fractures in the United States, 2005–2025. J Bone Miner Res 22:465–475PubMedCrossRefGoogle Scholar
  9. 9.
    Miller PD, Derman RJ (2010) What is the best balance of benefits and risks among anti-resorptive therapies for postmenopausal osteoporosis? Osteoporos Int 21:1793–1802PubMedCrossRefGoogle Scholar
  10. 10.
    Lewiecki EM (2009) Current and emerging pharmacologic therapies for the management of postmenopausal osteoporosis. J Womens Health (Larchmt) 18:1615–1626CrossRefGoogle Scholar
  11. 11.
    Komm BS, Kharode YP, Bodine PV, Harris HA, Miller CP, Lyttle CR (2005) Bazedoxifene acetate: a selective estrogen receptor modulator with improved selectivity. Endocrinology 146:3999–4008PubMedCrossRefGoogle Scholar
  12. 12.
    Miller PD, Chines AA, Christiansen C, Hoeck HC, Kendler DL, Lewiecki EM, Woodson G, Levine AB, Constantine G, Delmas PD (2008) Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study. J Bone Miner Res 23:525–535PubMedCrossRefGoogle Scholar
  13. 13.
    Silverman SL, Christiansen C, Genant HK, Vukicevic S, Zanchetta JR, de Villiers TJ, Constantine GD, Chines AA (2008) Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial. J Bone Miner Res 23:1923–1934PubMedCrossRefGoogle Scholar
  14. 14.
    Kanis JA, Johansson H, Oden A, McCloskey EV (2009) Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX. Bone 44:1049–1054PubMedCrossRefGoogle Scholar
  15. 15.
    Genant HK, Jergas M, Palermo L, Nevitt M, Valentin RS, Black D, Cummings SR, for the Study of Osteoporotic Fractures Research Group (1996) Comparison of semiquantitative visual and quantitative morphometric assessment of prevalent and incident vertebral fractures in osteoporosis. J Bone Miner Res 11:984–996PubMedCrossRefGoogle Scholar
  16. 16.
    Chesnut CHI, Skag A, Christiansen C, Recker R, Stakkestad JA, Hoiseth A, Felsenberg D, Huss H, Gilbride J, Schimmer RC, Delmas PD (2004) Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 19:1241–1249CrossRefGoogle Scholar
  17. 17.
    Black DM, Arden NK, Palermo L, Pearson J, Cummings SR, for the Study of Osteoporotic Fractures Research Group (1999) Prevalent vertebral deformities predict hip fractures and new vertebral deformities but not wrist fractures. J Bone Miner Res 14:821–828PubMedCrossRefGoogle Scholar
  18. 18.
    de Villiers TJ, Chines AA, Palacios S, Lips P, Sawicki AZ, Levine AB, Codreanu C, Kelepouris N, Brown JP (2011) Safety and tolerability of bazedoxifene in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled phase 3 trial. Osteoporos Int 22(2):567–576PubMedCrossRefGoogle Scholar
  19. 19.
    Delmas PD, Ensrud KE, Adachi JD, Harper KD, Sarkar S, Gennari C, Reginster JY, Pols HA, Recker RR, Harris ST, Wu W, Genant HK, Black DM, Eastell R (2002) Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J Clin Endocrinol Metab 87:3609–3617PubMedCrossRefGoogle Scholar
  20. 20.
    Cummings SR, Ensrud K, Delmas PD, LaCroix AZ, Vukicevic S, Reid DM, Goldstein S, Sriram U, Lee A, Thompson J, Armstrong RA, Thompson DD, Powles T, Zanchetta J, Kendler D, Neven P, Eastell R (2010) Lasofoxifene in postmenopausal women with osteoporosis. N Engl J Med 362:686–696PubMedCrossRefGoogle Scholar
  21. 21.
    Pfizer Inc (2008) FABLYN® (lasofoxifene tartrate) 0.5 mg tablets. NDA 22–242. Reproductive Health Drugs Advisory Committee Briefing Document, 08 September 2008. http://www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4381b1-02-Pfizer.pdf. Accessed 10 December 2009
  22. 22.
    Seeman E, Delmas PD (2006) Bone quality—the material and structural basis of bone strength and fragility. N Engl J Med 354:2250–2261PubMedCrossRefGoogle Scholar
  23. 23.
    Borah B, Dufresne TE, Chmielewski PA, Gross GJ, Prenger MC, Phipps RJ (2002) Risedronate preserves trabecular architecture and increases bone strength in vertebra of ovariectomized minipigs as measured by three-dimensional microcomputed tomography. J Bone Miner Res 17:1139–1147PubMedCrossRefGoogle Scholar
  24. 24.
    Eastell R, Barton I, Hannon RA, Chines A, Garnero P, Delmas PD (2003) Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res 18:1051–1056PubMedCrossRefGoogle Scholar
  25. 25.
    Bauer DC, Black DM, Garnero P, Hochberg M, Ott S, Orloff J, Thompson DE, Ewing SK, Delmas PD (2004) Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial. J Bone Miner Res 19:1250–1258PubMedCrossRefGoogle Scholar
  26. 26.
    Martino S, Cauley JA, Barrett-Connor E, Powles TJ, Mershon J, Disch D, Secrest RJ, Cummings SR (2004) Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst 96:1751–1761PubMedCrossRefGoogle Scholar
  27. 27.
    Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C, Delmas PD, Zanchetta JR, Stakkestad J, Gluer CC, Krueger K, Cohen FJ, Eckert S, Ensrud KE, Avioli LV, Lips P, Cummings SR, for the Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA 282:637–645PubMedCrossRefGoogle Scholar
  28. 28.
    Cummings SR, Eckert S, Krueger KA, Grady D, Powles TJ, Cauley JA, Norton L, Nickelsen T, Bjarnason NH, Morrow M, Lippman ME, Black D, Glusman JE, Costa A, Jordan VC (1999) The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 281:2189–2197PubMedCrossRefGoogle Scholar
  29. 29.
    Grady D, Ettinger B, Moscarelli E, Plouffe L Jr, Sarkar S, Ciaccia A, Cummings S (2004) Safety and adverse effects associated with raloxifene: multiple outcomes of raloxifene evaluation. Obstet Gynecol 104:837–844PubMedCrossRefGoogle Scholar
  30. 30.
    Archer DF, Pinkerton JV, Utian WH, Menegoci JC, de Villiers TJ, Yuen CK, Levine AB, Chines AA, Constantine GD (2009) Bazedoxifene, a selective estrogen receptor modulator: effects on the endometrium, ovaries, and breast from a randomized controlled trial in osteoporotic postmenopausal women. Menopause 16:1109–1115PubMedCrossRefGoogle Scholar
  31. 31.
    Pinkerton JV, Archer DF, Utian WH, Menegoci JC, Levine AB, Chines AA, Constantine GD (2009) Bazedoxifene effects on the reproductive tract in postmenopausal women at risk for osteoporosis. Menopause 16:1102–1108PubMedCrossRefGoogle Scholar
  32. 32.
    Harvey JA, Holm MK, Ranganath R, Guse PA, Trott EA, Helzner E (2009) The effects of bazedoxifene on mammographic breast density in postmenopausal women with osteoporosis. Menopause 16:1193–1196PubMedCrossRefGoogle Scholar
  33. 33.
    Carlson RV, Boyd KM, Webb DJ (2004) The revision of the Declaration of Helsinki: past, present and future. Br J Clin Pharmacol 57:695–713PubMedCrossRefGoogle Scholar
  34. 34.
    Black DM, Thompson DE, Bauer DC, Ensrud K, Musliner T, Hochberg MC, Nevitt MC, Suryawanshi S, Cummings SR, for the FIT Research Group (2000) Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. J Clin Endocrinol Metab 85:4118–4124PubMedCrossRefGoogle Scholar
  35. 35.
    Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, Chesnut CH III, Brown J, Eriksen EF, Hoseyni MS, Axelrod DW, Miller PD (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 282:1344–1352PubMedCrossRefGoogle Scholar

Copyright information

© International Osteoporosis Foundation and National Osteoporosis Foundation 2011

Authors and Affiliations

  • S. L. Silverman
    • 1
    • 9
  • A. A. Chines
    • 2
  • D. L. Kendler
    • 3
  • A. W. C. Kung
    • 4
  • C. S. Teglbjærg
    • 5
  • D. Felsenberg
    • 6
  • N. Mairon
    • 7
  • G. D. Constantine
    • 2
  • J. D. Adachi
    • 8
  • for the Bazedoxifene Study Group
  1. 1.Cedars-Sinai Medical Center and University of CaliforniaLos AngelesUSA
  2. 2.Pfizer IncCollegevilleUSA
  3. 3.Prohealth ResearchUniversity of British ColumbiaVancouverCanada
  4. 4.Department of MedicineThe University of Hong KongHong KongChina
  5. 5.Center for Clinical and Basic ResearchBallerupDenmark
  6. 6.Center of Muscle and Bone ResearchCharité University Medicine Berlin, Free University and Humboldt UniversityBerlinGermany
  7. 7.Wyeth PharmaceuticalsParisFrance
  8. 8.St. Joseph’s HealthcareMcMaster UniversityHamiltonCanada
  9. 9.OMC Clinical Research CenterBeverly HillsUSA

Personalised recommendations